Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 1, 2014, Pages 95-115

  Gu, Yi ^a   Wang, Jian ^a   Li, Ke ^a,b   Zhang, Li ^a   Ren, Hongcan ^a   Guo, Lixia ^a   Sai, Yang ^a   Zhang, Weihan ^a   Su, Weiguo ^a  

^a Hutchison MediPharma Limited   (China)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Allometric scaling; Disposition; Fruquintinib; HMPL 013; Modeling; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; FRUQUINTINIB; HMPL 013; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DOG; DRUG METABOLISM; DRUG PENETRATION; FEMALE; GASTROINTESTINAL TRACT; GLUCURONIDATION; HAPLORHINI; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; KIDNEY; LIVER; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ANGIOGENESIS INHIBITORS; ANIMALS; BENZOFURANS; BILE; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; DRUGS, INVESTIGATIONAL; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; MALE; METABOLIC DETOXICATION, DRUG; MICROSOMES, LIVER; MODELS, BIOLOGICAL; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOM ALLOCATION; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 84903815337     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2471-3     Document Type: Article

References (34)

1. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors. Clin Cancer Res 9:327-337 (Pubitemid 36109749)
2. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795-803
3. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389-4400 (Pubitemid 40775678)
4. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F (2006) Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11:753-764 (Pubitemid 44157563)
5. Cook KM, Figg WD (2010) Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60:222-243
6. Chow LQM, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896 (Pubitemid 350002890)
7. Iyer R, Fetterly G, Lugade A, Thanavala Y (2010) Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 11:1943-1955
8. Bhargava P, Robinson MO (2011) Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep 13:103-111
9. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH (2010) Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol Cancer Ther 9:3137-3144
10. Hellström M, Gerhardt H, Kalén M, Li X, Eriksson U, Wolburg H, Betsholtz C (2001) Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 153:543-553 (Pubitemid 34280141)
11. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272-7283
12. Patson B, Cohen BR, Olszanski AJ (2012) Pharmacokinetic evaluation of axitinib. Expert Opin Drug Metab Toxicol 8:259-270
13. Gu Y, Wang GJ, Wu XL, Zheng YT, Zhang JW, Ai H, Sun JG, Jia YW (2010) Intestinal absorption mechanisms of ginsenoside Rh2: stereoselectivity and involvement of ABC transporters. Xenobiotica 40:602-612
14. Kuhnz W, Gieschen H (1998) Predicting the oral bioavailability of 19-nortestosterone progestins in vivo from their metabolic stability in human liver microsomal preparations in vitro. Drug Metab Dispos 26:1120-1127 (Pubitemid 28516588)
15. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359
16. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, Macintyre F, Rance DJ, Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58 (Pubitemid 27438945)
17. Center for Drug Evaluation and Research FaDA (2001) Guidance for industry: bioanalytical method validation
18. Fura A, Vyas V, Humphreys W, Chimalokonda A, Rodrigues D (2008) Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compounds. Biopharm Drug Dispos 29:455-468
19. Mahmood I, Balian JD (1996) Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887-895 (Pubitemid 26343083)
20. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095 (Pubitemid 23211439)
21. Wilkinson GR, Shand DG (1975) Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390
22. Toutain PL, Bousquet-Melou A (2004) Plasma clearance. J Vet Pharmacol Ther 27:415-425 (Pubitemid 39665129)
23. Rowland M, Tozer T (2011) Clinical pharmacokinetics and pharmacodynamics: concepts and application, 4th edn. Lippincott Williams & Wilkins, a Wolters Kluwer business, New York
24. Toutain PL, Bousquet-Melou A (2004) Volumes of distribution. J Vet Pharmacol Ther 27:441-453 (Pubitemid 39665131)
25. Berezhkovskiy LM (2008) Prediction of the possibility of the second peak of drug plasma concentration time curve after iv bolus administration from the standpoint of the traditional multi-compartmental linear pharmacokinetics. J Pharm Sci 97:2385-2393
26. Rolan PE (1994) Plasma-protein binding displacement interactions-why are they still regarded as clinically important. Br J Clin Pharmacol 37:125-128
27. Benet LZ, Hoener BA (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115-121 (Pubitemid 34271114)
28. Tillement JP, Urien S, Chaumet-Riffaud P, Riant P, Bree F, Morin D, Albengres E, Barre J (1988) Blood binding and tissue uptake of drugs. recent advances and perspectives. Fundam Clin Pharmacol 2:223-238
29. Toutain PL, Bousquet-Melou A (2004) Plasma terminal half-life. J Vet Pharmacol Ther 27:427-439 (Pubitemid 39665130)
30. Poulin P, Jones RDO, Jones HM, Gibson CR, Rowland M, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Bjornsson T, Lave T, Yates JWT (2011) PHRMA CPCDC initiative on predictive models of human pharmacokinetics, Part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J Pharm Sci 100:4127-4157
31. Rowland M, Peck C, Tucker G (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51:45-73
32. Huang W, Lee SL, Yu LX (2009) Mechanistic approaches to predicting oral drug absorption. APS J 11:217-224
33. Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies. Pharm Res 20:1015-1021 (Pubitemid 36774272)
34. Niggebrugge AE, MacLauchlin C, Dai D, Ford LA, Menendez AT, Chilton AS (2002) A high throughput protein binding assay by cohesive turbulent flow liquid chromatography mass spectrometry to support drug discovery. In: The 50th ASMS conference on mass spectrometry and allied topics, Orlando, Florida